Biohaven reports positive patient data for autoimmune disease drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Raymond James on Biohaven Pharma (BHVN) with shares up 7%: 'Promising Degrader Data Sets Ahead of R&D Day'
May 27, 2026 10:16 AM EDTRaymond James analyst Chris Raymond reiterated a Strong Buy rating and $50.00 price target on Biohaven Pharma (NYSE: BHVN).
The analyst comments "Remain Strong Buy rated on BHVN shares following the announcement of positive preliminary data sets for degraders BHV-1300 and BHV-1400 in patients this morning... More
